Mundi Pharma signs co-sales agreement of ADHD therapy ‘Bisphentin’

Published: 2017-01-23 14:17:33

Updated: 2017-01-23 14:17:33

Mundi Pharma(CEO Myung-Sae Lee) signed a co-sales agreement of ‘Bisphentin Controlled-Release Cap(generic name: methylphenidate hydrochloride),’ an attention-deficit/hyperactivity disorder(ADHD) therapy, with Korea Pharma(CEO/Chairman Jae-Don Park).

Under the agreement, Korea Pharma will exclusively take charge in the Korean sales and marketing of Bisphentin.

Bisphentin has methylphenidate hy...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.